Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Parodis

Showing results (61-70 of 189) with videos related to

Pageof 19
Sort By:
Expert Opinion on Biological Therapy|December 21, 2018
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studiesIoannis Parodis, Sharzad Emamikia, Alvaro Gomez, et al.
Rheumatology Advances in Practice|April 21, 2025
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithmsJoão Botto, Nursen Cetrez, Dionysis Nikolopoulos, et al.
Lupus Science & Medicine|February 26, 2025
Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from SwedenAlvaro Gomez, Ioannis Parodis, Muna Saleh, et al.
Journal of Patient-Reported Outcomes|February 7, 2026
The value of EQ-5D-3L and EQ VAS as a patient-reported outcome measure for patients with ankylosing spondylitis in routine healthcare: an evaluation of construct validity and responsiveness based on the Swedish Rheumatology Quality RegisterKinza Degerlund-Maldi, Malin Regardt, Camilla Nystrand Länsman, et al.
Rheumatology (Oxford, England)|March 14, 2025
Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trialsGiorgia Grosso, Nefeli Giannopoulou, Alexander Tsoi, et al.
Expert Review of Clinical Immunology|February 4, 2026
Old and New autoantibodies in systemic lupus erythematosusIoannis Parodis, Dionysis Nikolopoulos, André Brylid, et al.
Nature Reviews. Disease Primers|January 25, 2020
Lupus nephritisHans-Joachim Anders, Ramesh Saxena, Ming-Hui Zhao, et al.
Nature Reviews. Rheumatology|November 12, 2021
Differentiating between UCTD and early-stage SLE: from definitions to clinical approachSavino Sciascia, Dario Roccatello, Massimo Radin, et al.
International Journal of Molecular Sciences|November 26, 2022
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of BelimumabIoannis Parodis, Alvaro Gomez, Julius Lindblom, et al.
Lupus Science & Medicine|July 22, 2021
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control studyIsak Samuelsson, Ioannis Parodis, Iva Gunnarsson, et al.
Pageof 19

Showing results (61-70 of 189) with videos related to

Sort By:
Pageof 19
Expert Opinion on Biological Therapy|December 21, 2018
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studiesIoannis Parodis, Sharzad Emamikia, Alvaro Gomez, et al.
Rheumatology Advances in Practice|April 21, 2025
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithmsJoão Botto, Nursen Cetrez, Dionysis Nikolopoulos, et al.
Lupus Science & Medicine|February 26, 2025
Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from SwedenAlvaro Gomez, Ioannis Parodis, Muna Saleh, et al.
Journal of Patient-Reported Outcomes|February 7, 2026
The value of EQ-5D-3L and EQ VAS as a patient-reported outcome measure for patients with ankylosing spondylitis in routine healthcare: an evaluation of construct validity and responsiveness based on the Swedish Rheumatology Quality RegisterKinza Degerlund-Maldi, Malin Regardt, Camilla Nystrand Länsman, et al.
Rheumatology (Oxford, England)|March 14, 2025
Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trialsGiorgia Grosso, Nefeli Giannopoulou, Alexander Tsoi, et al.
Expert Review of Clinical Immunology|February 4, 2026
Old and New autoantibodies in systemic lupus erythematosusIoannis Parodis, Dionysis Nikolopoulos, André Brylid, et al.
Nature Reviews. Disease Primers|January 25, 2020
Lupus nephritisHans-Joachim Anders, Ramesh Saxena, Ming-Hui Zhao, et al.
Nature Reviews. Rheumatology|November 12, 2021
Differentiating between UCTD and early-stage SLE: from definitions to clinical approachSavino Sciascia, Dario Roccatello, Massimo Radin, et al.
International Journal of Molecular Sciences|November 26, 2022
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of BelimumabIoannis Parodis, Alvaro Gomez, Julius Lindblom, et al.
Lupus Science & Medicine|July 22, 2021
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control studyIsak Samuelsson, Ioannis Parodis, Iva Gunnarsson, et al.
Pageof 19